Study Population Gender Age Study group Observation period Treatment outcome Results Conclusion
Male/female Years
Yüce et al. [15] Female osteoporotic patients with stage 2 or 3 MRONJ underwent surgical treatment of MRONJ Control: 0/14 Control:
73.64 (SD 5.49) 		Control (n = 14): treated with sequestrectomy and bone curettage without application of CGF 6 months Treatment was considered successful if had soft tissue coverage in the surgical site without signs of infection and/or necrotic bone. Control: 6 healed (42.9%),
8 unhealed (57.1%) 		Local application of CGF appears to be an effective approach to the surgical treatment by improving tissue regeneration (P = 0.232)
Test: 0/14 Test:
73.57 (SD 5.1) 		Test (n =14): treated with a local application of CGF on the surgical site after removing the necrotic bone Test: 11 healed (78.6%),
3 unhealed (21.4%)
Park et al. [17] Patients with stage 1 - 3 MRONJ and underwent surgical treatment of MRONJ. Control: 3/22 75.24 Control (n = 25): surgical debridement of MRONJ lesion followed by application of L-PRF on bony defect Control: 6 - 26 months Treatment was considered successful if had mucosal coverage with absence of clinical or radiographical evidence of MRONJ at 4 weeks postoperatively. - Complete resolution.
Control: 9 patients (36%); test:
18 patients (60%).
- Delayed resolution.
Control: 13 patients (52%); test:
11 patients (36.7%).
- No resolution.
Control: 3 patients (12%); test:
1 patient (3.3%). 		L-PRF with BMP-2 therapy led to beneficial outcomes with complete resolution of the lesions, which were statistically significant when compared to L-PRF therapy alone (P = 0.028)
Test: 29/1 75.2 Test (n = 30): surgical debridement of MRONJ lesion and application of L-PRF and rhBMP-2 on bony defect Test: 6 - 31 months
Guo and Guo [20] Patients with stage 2 or 3 MRONJ and underwent surgical treatment of MRONJ. Control: 10/8 62.17 (SD 2.8) Control (n = 18): treated with conventional approach-sequestrectomy and curettage 30 months Treatment was considered successful if had complete mucosal coverage without bone exposure, fistula and relapse Control: 4 healed (22.22%),
14 relapse (77.78%) 		The test group's rate of treatment success was significantly greater
(P = 0.005)
Test: 6/4 63.5 (SD 3.38) Test (n = 10): treated with sequestrectomy and curettage with cortical perforations of the residual healthy bone. Test: 8 healed (80%),
2 relapse (20%)
Szentpeteri et al. [21] Patients with stage 2 or 3 MRONJ and underwent surgical treatment of MRONJ. 74/27 Control: 63.97 Control (n = 73): surgical open flap debridement of MRONJ lesion T1 = 1 week;
T2 = 2 weeks;
T3 = 1 month;
T4 = 3 months;
T5 = 6 months;
T6 = 1 year 		Treatment was considered successful if had staging improvement according to the AAOMS, no relapse.
Osteonecrosis assessed by X-ray 		- Wound healing.
Control: 38 cases (58.46%); test:
23 cases (82.14%).
- Down-staging.
Control: l54 cases (77.14%); test:
100% of cases.
- Relapse.
Control: 25 cases (65.78%); test:
5 cases (21.73%) 		PRF membrane-assisted surgical therapy greatly increased stage improvement and healing rates (P = 0.022) and down staging (P = 0.005) as well as significantly decreased relapse rates (P < 0.001)
Test: 68.42 Test (n = 28): surgical open flap debridement of MRONJ lesion and defect coverage with 2 PRF membranes.
Şahin et al. [22] Patients with stage 2 or 3 MRONJ and underwent surgical treatment of MRONJ 7/14 68.04 (SD 9.82) Ultrasonic piezoelectric bone surgery was used to remove the necrotic bone. Following debridement, the patient's peripheral blood was centrifuged to obtain L-PRF, which was then administered to the necrotic site T1 = 1 month;
T2 = 3 months;
T3 = 6 months;
T4 = 12 months 		Treatment was considered successful if had complete mucosal, bone covering and the absence of the symptom T1 = 2 stage III patients had delayed healing. T2, T3, T4 = all patients had complete mucosal healing The surgical procedure shown yields encouraging results.

MRONJ = medication-related osteonecrosis of the jaw; T = follow-up time; CGF = concentrated growth factor; PRF = platelet-rich fibrin; L-PRF = leukocyte rich and platelet-rich fibrin; BMP-2 = bone morphogenetic protein-2; AAOMS = The American Association of Oral and Maxillofacial Surgeons; SD = standard deviation.